Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02923531 · ClinicalTrials.gov registry record · Phase 1
Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
A Phase 1 study, sponsored by X4 Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02923531: Clinical Trial Phase 1 study, sponsored by X4 Pharmaceuticals.
NCT02923531 is a Phase 1 study that was terminated before completion, run by X4 Pharmaceuticals. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02923531, a Phase 1 study, was terminated before completion, sponsored by X4 Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of X4P-001 plus nivolumab is safe and tolerable. Secondly, the study will investigate if adding X4P-001 to nivolumab treatment has an effect on the body and the cancer tumor, in participants receiving nivolumab but not exhibiting a radiological response.
Primary Outcome
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Drug-related TEAEs: TEAEs with possible, probable, definite, or missing relationship to study medication (X4P-001 or Nivolumab). Serious AEs: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an importan
Interventions
- DRUG Nivolumab
- DRUG X4P-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-12-07 |
| Est. Completion | 2018-08-08 |
| Phase | Phase 1 |
Why NCT02923531 stopped before completion
NCT02923531 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02923531 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02923531 about?
NCT02923531 is a clinical study titled "Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma". The purpose of this study is to determine if the combination of X4P-001 plus nivolumab is safe and tolerable. Secondly, the study will investigate if adding X4P-001 to nivolumab treatment has an effect on the body and the cancer tumor, in participants receiving nivolumab but not exhibiting a radiolo...
What is the current status of trial NCT02923531?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2016-12-07. Estimated completion is 2018-08-08.
What interventions are being tested in trial NCT02923531?
The interventions under investigation include: Nivolumab (DRUG), X4P-001 (DRUG).
Who is sponsoring clinical trial NCT02923531?
This trial is sponsored by X4 Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02923531's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI